4//SEC Filing
Teehan Brendan 4
Accession 0001415889-24-010603
CIK 0001070494other
Filed
Apr 8, 8:00 PM ET
Accepted
Apr 9, 6:00 PM ET
Size
9.5 KB
Accession
0001415889-24-010603
Insider Transaction Report
Form 4
Teehan Brendan
EVP, COO, Head of Commercial
Transactions
- Sale
Common Stock
2024-04-08$17.87/sh−2,568$45,890→ 38,796 total - Exercise/Conversion
Restricted Stock Units
2024-04-05−5,024→ 10,048 total→ Common Stock (5,024 underlying) - Exercise/Conversion
Common Stock
2024-04-05+5,024→ 41,364 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7875 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The restricted stock units vest in four equal annual installments beginning April 5, 2023.
Documents
Issuer
ACADIA PHARMACEUTICALS INC
CIK 0001070494
Entity typeother
Related Parties
1- filerCIK 0001891900
Filing Metadata
- Form type
- 4
- Filed
- Apr 8, 8:00 PM ET
- Accepted
- Apr 9, 6:00 PM ET
- Size
- 9.5 KB